The publication of the Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies study [ARBITER 6-HALTS (ClinicalTrials.gov number, NCT00397657)] adds fuel to a controversy regarding the issue of combination therapy with ezetimibe in the prevention of cholesterol-related atherogenic disease [Taylor et al. 2009 ]. Patients who were at high risk for atherosclerotic vascular disease and receiving statin treatment were randomized to adjunctive therapy with either ezetimibe or niacin over a 14 month period. Progression of atherosclerosis was judged from changes in common carotid artery intima-media thickness.
The study-population consisting of men and women older than 30 years of age was derived from two tertiary-care hospitals in the Washington DC area. As illustrated in the flow diagram of Figure 1 , target doses of ezetimibe (10 mg/day) or niacin (2,000 mg/day) were administered to randomized subjects on a background of statin therapy. Baseline risk factors in the subset of subjects who completed the 14-month study are documented in Figure 2 . Subjects had either known coronary or vascular atherosclerotic disease or a coronary heart disease equivalent including the presence of diabetes mellitus or a positive calcium score. In addition, hypertension was the predominantly reported risk factor in the study population ( Figure 2 ). The primary prespecified study end-point was the between-group difference in common carotid intima-media thickness by B-mode ultrasonography at 14 months in subjects randomized to either ezetimibe or extended-release (ER) niacin on a background of statin treatment (mostly simvastatin or atorvastatin). Changes in lipid profile, the composite end-point of myocardial infarction or revascularization, hospital admission for acute coronary syndrome, and death from coronary artery disease, adverse effects leading to therapy discontinuation or health-related quality of life were defined as secondary end-points. As illustrated in Figure 3 , both mean and maximal carotid intima-media thicknesses, in the subset of subjects reaching the specified 14-month end-point, were significantly reduced in subjects randomized to ER niacin/statin within 8 and 14 months after treatment initiation. In contrast, common carotid intima-media thickness did not change in the patients randomized to the combined treatment of ezetimibe/statin. The authors' conclusion is that the study demonstrated a superiority of the combination of niacin/statin over ezetimibe/statin in reversing intima-media thickness in patients at high risk for cardiovascular events and a lipid profile in which average LDL and HDL cholesterol levels were below 100 mg/dL and between 50 and 55 mg/dL, respectively [Taylor et al. 2009 ]. Although the trial was not powered for clinical outcomes, the rate of cardiovascular events was less in subjects randomized to the niacin arm of the study.
Experience with niacin as a cardioprotective agent has a long history [1975] . Multiple studies demonstrate a beneficial effect of niacin on both LDL and HDL-cholesterol fractions and decreases in large plaque formation and in the progression of atherogenesis [Lee et al. 2009; Cziraky et al. 2008; Goldberg, 1998; McKenney et al. 1998; Keenan et al. 1991; Alderman et al. 1989; Blankenhorn et al. 1987; Walldius and Wahlberg, 1985; Nessim et al. 1983] . The data from ARBITER 6-HALTS provides additional information as to the value of niacin therapy in stalling progression of vascular atherosclerosis and, in a sense, suggests that the effect of niacin in reversing common carotid intima-media thickness is comparable to that obtained with statin therapy alone.
Precautionary comments about generalization of the findings in ARBITER 6-HALTS as the regimen of choice relates to the premature, and possibly unjustified, decision of stopping the trial before all patients completed the 14-month study on the basis of changes in the surrogate primary end-point. This is a particular concern since intima-media thickness represents a soft marker for hard end-point clinical events. In the US Preventive Services Task Force analysis, measures of carotid intima-media thickness had no predictive value as an emerging risk factor for primary prevention of CHD [Helfand et al. 2009 ]. We should also be prudent in over interpreting the Therapeutic Advances in Cardiovascular Disease 4 (2) results of ARBITER 6-HALTS as proof that the benefit induced by the combination of niacin and statin are accounted for by the improvement in HDL-cholesterol levels since in the study the treatment impacted both LDL-and HDL-cholesterol as well as triglycerides [Taylor et al. 2009 ]. In keeping with this interpretation, Kastelin and Bots [Kastelein and Bots, 2009] commented that the use of combination therapy directed to lowering of LDL-cholesterol and increasing HDL-cholesterol may be a more effective approach to reducing risk of clinical events for high cardiovascular risk patients. While the small patient population in the ARBITER 6-HALTS does not have the size to provide definitive evidence on this issue, we should not forget that the cholesteryl ester transfer protein inhibitor, torcetrapib, did not lead to a significant decrease in the progression of coronary atherosclerosis despite demonstrating a robust effect in increasing HDL-cholesterol [Nissen et al. 2007 ].
The failure of ezetimibe to reduce common carotid artery intima-media thickness does not negate potential benefits of this agent as an adjunct anti-lipidemic agent since the ARBITER 6-HALTS trial did not include a placebo control arm. Although ezetimibe acts as a specific antagonist of the Niemann-Pick C1-Like 1 (NPC1L1) protein to prevent the absorption of cholesterol into the circulation at the level of the [Farmer, 2009] trials. In the ENHANCE trial [Kastelein et al. 2008; Kastelein et al. 2005] , the magnitude of the change in intima-media thickness with the combination of ezetimibe and simvastatin was not different than that observed with simvastatin alone in patients with familial hypercholesterolemia. Interestingly, the magnitude of the average change in intima-media thickness in the patients randomized to ezetimibe/simvastatin (À0.0111±0.0038 mm) in the ENHANCED trial [Kastelein et al. 2008 ] is comparable to that reported in the ARBITER 6-HALTS [Taylor et al. 2009 ] for the group assigned to the niacin therapy (À0.0142±0.0041 mm). While differences in methodology, length of the studies, patients' medical history and demographics precludes a direct comparison, the posit question is whether the data do suggest a partial benefit of the combination therapy on the surrogate marker for vascular remodeling. Nevertheless, with the publication of the ARBITER 6-HALTS [Taylor et al. 2009] , it is clear that the use of ezetimibe as an anti-lipidemic agent should be considered only as a third drug of choice [Mitka, 2008] .
In summary, the publication of the ARBITER 6-HALTS [Taylor et al. 2009 ] study enhances awareness of the effective use of niacin as an adjunctive lipid lowering strategy directed to raising HDL-cholesterol over a background of statin therapy with a primary impact on reducing LDL-cholesterol. The short-comings of the published trial in terms of premature termination, small sample size, and the use of a potentially weak surrogate end-point to assess the global impact of the treatment combinations in terms of prevention of cardiovascular events or mortality will continue to limit the long-term expectations associated with this approach. While clinical experience and evidence-based medicine assures a continual role of niacin in the managements of patients with dyslipidemia and high risk for coronary and vascular events, it would be premature to alter treatment approaches until data are available from the currently following on-going large clinical trials: (1) [Windler et al. 2007] ; and (4) the effect of combination of niacin and laropiprant Paolini et al. 2008] in patients with a history of circulatory disorders (HPS2-THRIVE; ClinicalTrials.gov. number, NCT00461630). These trials may become the definitive arbiter in settling this matter.
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